Latest operating income for LBRX: $-95M.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
LB PharmaceuticalsCommon Stock's operating income stands at $-95M as of June 2026. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Open the history chart to see whether LB PharmaceuticalsCommon Stock's operating income is expanding or contracting. Sustained growth in operating income can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.
The history chart shows how LB PharmaceuticalsCommon Stock's operating income evolved across reporting periods, while the comparison chart places LBRX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, operating income is commonly used to spot outliers. LB PharmaceuticalsCommon Stock's reading of $-95M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.